Tissue Regenix Group plc TSSNF OTC

Other OTC • Healthcare • Biotechnology • GB • USD

SharesGrow Score

44/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Tissue Regenix Group plc (TSSNF) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 41/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

44/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

43/100

→ Income

✓

GROWTH

100/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — TSSNF

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.01

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.01

Book Value / Share$0.00

Revenue / Share$0.41

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$-1.80	$1.16M	$-13.4M	-1153.2%
2016	$0.00	$1.57M	$-10.68M	-678.2%
2017	$-1.00	$5.23M	$-9.22M	-176.2%
2018	$-0.70	$11.62M	$-8.19M	-70.5%
2019	$-0.60	$13.03M	$-6.97M	-53.5%
2020	$-0.22	$12.83M	$-9.71M	-75.7%
2021	$-0.05	$14.36M	$-3.48M	-24.3%
2022	$-0.03	$19.87M	$-2.19M	-11%
2023	$-0.02	$29.49M	$-1.71M	-5.8%
2024	$-0.01	$28.65M	$-713K	-2.5%